NOVOCURE LTD (NVCR)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for NVCR
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| NVCR | Former Chief Financial Officer of Intersect ENT, Inc. | 68 | [] | ["Audit"] | 2026 |
Biography sourced from the proxy statement filing.
Ms. Hilleman retired from Intersect ENT, Inc., a medical device company, where she served as Chief Financial Officer from June 2014 to December 2019. Prior to joining Intersect ENT, Ms. Hilleman served as Chief Financial Officer of several public life sciences companies including Ocera Therapeutics, Inc. from 2013 to 2014, Amyris, Inc., from 2008 to 2012, and Symyx Technologies, Inc. from 1997 to 2007. Education: A.B. in History, Brown University; M.B.A., Wharton Graduate School of Business. Other Public Company Directorships: Director of Omada Health, Inc. since 2018 and of SI-Bone, Inc. since 2019. Formerly a director of HilleVax from 2020 to September 2025, Cutera, Inc. from July to November 2024, Minerva Neurosciences, Inc. from 2018 to 2024 and of Talis Biomedical from 2021 to 2022. We believe that Ms. Hilleman is qualified to serve on our Board due to her business and accounting experience serving as an executive and director of several biotechnology and oncology companies.